Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
IDT Australia Limited ( (AU:IDT) ) just unveiled an announcement.
IDT Australia Limited reported a 30% increase in quarterly revenue, reaching $4.1 million, driven by new contract wins and a strong pipeline of potential contracts totaling $62 million. The company experienced significant growth in its Active Pharmaceutical Ingredients vertical, which is expected to positively impact its Advanced Therapies and Specialty Orals segments. Despite global trade uncertainties, IDT’s outlook remains positive, with new contracts and proposals indicating robust future growth opportunities.
More about IDT Australia Limited
IDT Australia Limited (ASX: IDT) is an Australian pharmaceutical manufacturing company located in Boronia, Victoria. The company specializes in developing and producing high potency and high containment pharmaceutical products for both local and international clients. IDT’s facilities are cGMP compliant and regularly audited by the US FDA and Australian TGA. The company offers comprehensive services for new drug development, scale-up, and commercial active drug manufacture, as well as various oral and injectable finished drug dose forms.
Average Trading Volume: 409,634
Technical Sentiment Signal: Sell
Current Market Cap: A$45.49M
For an in-depth examination of IDT stock, go to TipRanks’ Stock Analysis page.